Characterization of Mycophenolate Mofetil Gastrointestinal Toxicity and Risk Factors for Severe Disease and Poor Prognosis.
作者信息
Bhattacharya Sumona, Stoleru Gianna, Patel Preet, Abutaleb Ameer, Stashek Kristen, Cross Raymond K
机构信息
Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
University of Maryland School of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Baltimore, MD, USA.
出版信息
Inflamm Bowel Dis. 2022 May 4;28(5):811-814. doi: 10.1093/ibd/izab254.
Abstract
摘要
相似文献
1
Characterization of Mycophenolate Mofetil Gastrointestinal Toxicity and Risk Factors for Severe Disease and Poor Prognosis.
Inflamm Bowel Dis. 2022 May 4;28(5):811-814. doi: 10.1093/ibd/izab254.
2
Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
Clin Transplant. 2014 Jul;28(7):783-8. doi: 10.1111/ctr.12379. Epub 2014 Jun 1.
3
Mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant patients.
Expert Rev Pharmacoecon Outcomes Res. 2009 Feb;9(1):29-32. doi: 10.1586/14737167.9.1.29.
4
Improvement in Severe Mycophenolic Acid-associated Gastrointestinal Symptoms after Changing Enteric-coated Mycophenolate Sodium to Mizoribine in Renal Transplant Recipients: Two Case Reports.
Intern Med. 2016;55(15):2005-10. doi: 10.2169/internalmedicine.55.5968. Epub 2016 Aug 1.
5
Unusually late-onset mycophenolate mofetil-related colitis.
Am J Health Syst Pharm. 2014 Nov 1;71(21):1858-61. doi: 10.2146/ajhp140085.
6
Acute colonic pseudo-obstruction caused by mycophenolate mofetil in a kidney transplant recipient.
Exp Clin Transplant. 2015 Apr;13(2):196-9. doi: 10.6002/ect.2013.0264. Epub 2014 Jun 9.
7
Safety profile of mycophenolate mofetil: a response.
Bone Marrow Transplant. 2001 Apr;27(8):892. doi: 10.1038/sj.bmt.1703018.
8
Effects of mycophenolate mofetil on the gastrointestinal system and kidney graft function: early experience at one center.
Transplant Proc. 2002 Sep;34(6):2093-5. doi: 10.1016/s0041-1345(02)02865-8.
9
[Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].
Hautarzt. 2000 Feb;51(2):63-9. doi: 10.1007/s001050050013.
10
Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
Pharmacoeconomics. 2008;26(11):951-67. doi: 10.2165/00019053-200826110-00007.
引用本文的文献
1
The Anti-Lupus Plate: Mapping Nutritional Interventions to Inflammatory Pathways in Systemic Lupus Erythematosus.
Food Sci Nutr. 2025 Sep 1;13(9):e70890. doi: 10.1002/fsn3.70890. eCollection 2025 Sep.
2
Exploring the etiology of colitis: insights from gut microbiota research.
Gut Microbes. 2025 Dec;17(1):2512010. doi: 10.1080/19490976.2025.2512010. Epub 2025 Jun 2.
3
MMF Is an Effective and Safer Treatment Options for Treatment-Naïve Patients With Autoimmune Hepatitis Compared to Azathioprine: A Systematic Review and Meta-Analysis.
J Dig Dis. 2025 Mar-Apr;26(3-4):113-128. doi: 10.1111/1751-2980.13348. Epub 2025 May 19.
4
Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients.
Curr Issues Mol Biol. 2024 Dec 24;47(1):2. doi: 10.3390/cimb47010002.
5
A GC-MS-based untargeted metabolomics approach for comprehensive metabolic profiling of mycophenolate mofetil-induced toxicity in mice.
Front Mol Biosci. 2024 Mar 7;11:1332090. doi: 10.3389/fmolb.2024.1332090. eCollection 2024.
本文引用的文献
1
Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation.
Ann Gastroenterol. 2015 Jul-Sep;28(3):366-373.
2
Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients.
Clin Transplant. 2014 Nov;28(11):1244-8. doi: 10.1111/ctr.12452. Epub 2014 Sep 16.
3
Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis.
Histopathology. 2013 Nov;63(5):649-58. doi: 10.1111/his.12222. Epub 2013 Sep 11.
4
Microscopic features associated with mycophenolate mofetil in gastric and colonic biopsies.
Histopathology. 2012 Nov;61(5):993-7. doi: 10.1111/j.1365-2559.2012.04305.x.
5
Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil.
Mod Pathol. 2009 Jun;22(6):737-43. doi: 10.1038/modpathol.2009.44. Epub 2009 Mar 27.
6
Crohn's-like changes in the colon due to mycophenolate?
Colorectal Dis. 2005 Jan;7(1):27-34. doi: 10.1111/j.1463-1318.2004.00695.x.
7
Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern.
Int J Surg Pathol. 2003 Oct;11(4):295-302. doi: 10.1177/106689690301100406.
8
Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus.
J Rheumatol. 2003 Jul;30(7):1508-12.
9
Risk factors that influence the incidence and severity of MMF adverse events in renal transplant patients: relationship with corticosteroid dosage, renal function, sex, and patient age.
Transplant Proc. 1999 Sep;31(6):2270-1. doi: 10.1016/s0041-1345(99)00333-4.
10
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
N Engl J Med. 1987 Dec 24;317(26):1625-9. doi: 10.1056/NEJM198712243172603.
Zotero 插件